0001140361-23-020660.txt : 20230426 0001140361-23-020660.hdr.sgml : 20230426 20230426211944 ACCESSION NUMBER: 0001140361-23-020660 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230424 FILED AS OF DATE: 20230426 DATE AS OF CHANGE: 20230426 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Ronil A. CENTRAL INDEX KEY: 0001974660 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34079 FILM NUMBER: 23851483 MAIL ADDRESS: STREET 1: 37000 GRAND RIVER AVE STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ocuphire Pharma, Inc. CENTRAL INDEX KEY: 0001228627 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113516358 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 BUSINESS PHONE: 248-681-9815 MAIL ADDRESS: STREET 1: 37000 GRAND RIVER AVE. STREET 2: SUITE 120 CITY: FARMINGTON HILLS STATE: MI ZIP: 48335 FORMER COMPANY: FORMER CONFORMED NAME: REXAHN PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050516 FORMER COMPANY: FORMER CONFORMED NAME: CORPORATE ROAD SHOW DOT COM INC DATE OF NAME CHANGE: 20030423 3 1 form3.xml X0206 3 2023-04-24 0 0001228627 Ocuphire Pharma, Inc. OCUP 0001974660 Patel Ronil A. C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS MI 48335 true SVP, Operations & Bus. Dev. Common Stock 22304 D Employee Stock Option (right to buy) 6.04 2031-03-24 Common Stock 18000 D Employee Stock Option (right to buy) 5.37 2031-06-30 Common Stock 20000 D Employee Stock Option (right to buy) 2.9 2032-01-27 Common Stock 18800 D Employee Stock Option (right to buy) 2.24 2032-08-31 Common Stock 15000 D Employee Stock Option (right to buy) 3.5 2033-01-09 Common Stock 25956 D The option vests in twenty-four (24) equal monthly increments of 750 shares on the last day of each month from April 2021 through March 2023. 5,000 shares vested on June 30, 2022, then 416 shares vest at the end of each month from July 2022 through May 2025, and 440 shares vest at the end of June 2025. The option vested with respect to 4,700 shares on January 28, 2023, and then with respect to 391 shares on the last day of each month from February 2023 through December 2025 and with respect to 415 shares at the end of January 2026. The option vests with respect to 3,750 shares on September 1, 2023, and then with respect to 312 shares on the last day of each month from September 2023 through July 2026 and with respect to 330 shares at the end of August 2026. 25% of the shares subject to the option vest on the first anniversary of the grant date, with the balance vesting quarterly in 12 equal installments thereafter. Exhibit 24, Power of Attorney, is attached. /s/ Emily J. Johns, by Power of Attorney 2023-04-26 EX-24 2 brhc20052049_ex24.htm EXHIBIT 24
Exhibit 24
POWER OF ATTORNEY
 
The undersigned hereby constitutes and appoints each of Amy Rabourn, Emily J. Johns, Lauren Legner, and Stephanie Swan signing singly, his or her true and lawful attorney-in-fact to:
 
1.          execute for and on behalf of the undersigned, with respect to the undersigned’s position as a director and/or officer of Ocuphire Pharma, Inc. (the “Company”), Form ID and Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
 
2.          do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or Forms 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange, stock market or similar authority; and
 
3.          take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, and in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
 
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.
 
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.
 
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of April 20, 2023.
/s/ Ronil Patel


Ronil A. Patel